Validation of the McIntyre And Rosenblat Rapid Response Scale (MARRRS) in Adults with Treatment-Resistant Depression Receiving Intravenous Ketamine Treatment

Cuijpers, 2014, What is the threshold for a clinically relevant effect? The case of major depressive disorders, Depress. Anxiety, 31, 374, 10.1002/da.22249 Faries, 2000, The responsiveness of the Hamilton Depression Rating Scale, J. Psychiatr. Res., 34, 3, 10.1016/S0022-3956(99)00037-0 Geddes, 2009, Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials, Br. J. Psychiatry, 194, 4, 10.1192/bjp.bp.107.048504 Guo, 2015, Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters, Am. J. Psychiatry, 172, 1004, 10.1176/appi.ajp.2015.14050652 Hershenberg, 2020, Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression, J. Affect. Disord., 266, 22, 10.1016/j.jad.2020.01.108 McIntyre, 2020, In vivo phenotyping, mechanism-informed treatments, domain-based psychopathology and nomological networks: A strategy for treatment discovery and development in bipolar depression, Bipolar Disord, 22, 657, 10.1111/bdi.13026 McIntyre, 2020, The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis, J. Affect. Disord., 276, 576, 10.1016/j.jad.2020.06.050 McIntyre, 2013, Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions, Depress. Anxiety, 30, 515, 10.1002/da.22063 McIntyre, 2005, Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale, CMAJ, 173, 1327, 10.1503/cmaj.050786 McIntyre, 2015, Treating to target in major depressive disorder: response to remission to functional recovery, CNS Spectr, 20, 20 McIntyre, 2020, The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder, Bipolar Disord, 22, 831, 10.1111/bdi.12941 McIntyre, 2000, The Effectiveness of Repeated Intravenous Ketamine on Depressive Symptoms, Suicidal Ideation and Functional Disability in Adults with Major Depressive Disorder and Bipolar Disorder: Results from the Canadian Rapid Treatment Center of Excellence, J. Affect. Disord., 274, 903, 10.1016/j.jad.2020.05.088 McIntyre, R.S., Rosenblat, J.D., Nemeroff, C.B., Sanacora, G., Murrough, J.W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D.V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J.G., Lee, Y., Lui, L.M.W., Mansur, R.B., Papakostas, G.I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A.H., Zarate, C.A., Jr, Stahl, S., 2021. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am. J. Psychiatry appiajp202020081251. Meltzer-Brody, 2018, Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials, Lancet, 392, 1058, 10.1016/S0140-6736(18)31551-4 Murrough, 2013, Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial, Am. J. Psychiatry, 170, 1134, 10.1176/appi.ajp.2013.13030392 Newport, 2015, Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression, Am. J. Psychiatry, 172, 950, 10.1176/appi.ajp.2015.15040465 Papakostas, 2020, Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis, J. Clin. Psychiatry, 81, 10.4088/JCP.19r12889 Peyrovian, 2020, Registered clinical trials investigating ketamine for psychiatric disorders, J. Psychiatr. Res., 127, 1, 10.1016/j.jpsychires.2020.03.020 Ragguett, 2019, Keeping up with the clinical advances: depression, CNS Spectr, 24, 25, 10.1017/S1092852919001159 Rodrigues, 2020, Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence, Expert Opin. Drug Saf., 1 Rosenblat, 2019, Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression, J. Affect. Disord., 243, 116, 10.1016/j.jad.2018.09.027 Ruhé, 2005, Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores, Compr. Psychiatry, 46, 417, 10.1016/j.comppsych.2005.03.001 Rush, 2020, Improving Depression Outcome by Patient-Centered Medical Management, FOCUS, 10.1176/appi.focus.18207 Sanacora, 2017, A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders, JAMA Psychiatry, 74, 399, 10.1001/jamapsychiatry.2017.0080 Stahl, 2019, Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity, CNS Spectr, 24, 461, 10.1017/S1092852919001470 Stevens, 2012 Suzuki, 2005, A three-factor model of the MADRS in major depressive disorder, Depression and Anxiety, 10.1002/da.20058 Thase, 1997, When at first you don't succeed: sequential strategies for antidepressant nonresponders, J. Clin. Psychiatry, 58, 23 Trivedi, 2004, Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project, Arch. Gen. Psychiatry, 61, 669, 10.1001/archpsyc.61.7.669 Trivedi, 2004, Psychol. Med., 34, 73, 10.1017/S0033291703001107 Vrieze, 2014, Dimensions in major depressive disorder and their relevance for treatment outcome, J. Affect. Disord., 155, 35, 10.1016/j.jad.2013.10.020